Insider plans 200K Taysha Gene Therapies (NASDAQ: TSHA) share sale

Rhea-AI Filing Summary

Taysha Gene Therapies insider Sukumar Nagendran has filed a Form 144 notice to sell 200,000 shares of common stock. The planned sale has an aggregate market value of $996,000, with trades expected around 01/12/2026 through Jefferies LLC on the Nasdaq market. The filing notes 273,920,000 shares of common stock outstanding.

The 200,000 shares were acquired via vested stock option grants from Taysha Gene Therapies, Inc. on 05/31/2023 (111,324 shares) and 01/02/2024 (88,676 shares. In the past three months, Nagendran has already sold 110,125 shares on 11/28/2025 for gross proceeds of $522,774.39 and 260,047 shares on 12/01/2025 for gross proceeds of $1,172,837.97.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Avenue 4th Fl New York NY 10022	200000	996000.00	273920000	01/12/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/31/2023	Vested Stock Option Grant	Taysha Gene Therapies, Inc.			111324	05/31/2023	N/A
Common	01/02/2024	Vested Stock Option Grant	Taysha Gene Therapies, Inc.			88676	01/02/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sukumar Nagendran 3000 PEGASUS PARK DRIVE SUITE 1430 Dallas TX 75247	Common	11/28/2025	110125	522774.39
Sukumar Nagendran 3000 PEGASUS PARK DRIVE SUITE 1430 Dallas TX 75247	Common	12/01/2025	260047	1172837.97

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TSHA Form 144 filing disclose?

The Form 144 filing discloses that Sukumar Nagendran intends to sell 200,000 shares of Taysha Gene Therapies common stock, with an aggregate market value of $996,000, through Jefferies LLC on the Nasdaq around 01/12/2026.

How many Taysha Gene Therapies (TSHA) shares are outstanding in this Form 144?

The Form 144 states that 273,920,000 shares of Taysha Gene Therapies common stock were outstanding. This figure provides context for the planned 200,000-share sale.

How were the TSHA shares in this Form 144 acquired?

The 200,000 common shares covered by the notice were acquired via vested stock option grants from Taysha Gene Therapies, Inc. on 05/31/2023 for 111,324 shares and on 01/02/2024 for 88,676 shares, both listed with the nature of payment as N/A.

Which broker and exchange are involved in the TSHA Form 144 sale?

The planned sale of 200,000 common shares is to be executed through Jefferies LLC, located at 520 Madison Avenue, 4th Floor, New York, NY 10022, with the shares to be sold on the Nasdaq exchange.

What TSHA stock sales has the insider made in the last three months?

The filing reports that Sukumar Nagendran sold 110,125 common shares on 11/28/2025 for $522,774.39 in gross proceeds and 260,047 common shares on 12/01/2025 for $1,172,837.97 in gross proceeds.

What assurance does the insider give in this TSHA Form 144?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.